



THE UNIVERSITY OF CHICAGO

# ANNUAL UPDATES FROM ASH 2023

## ACCREDITATION AND CREDIT DESIGNATION STATEMENT

**PHYSICIAN CREDIT:** The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 6.50 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**NURSING CREDIT:** University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Participants who successfully complete the entire activity and complete an evaluation form will earn 6.50 contact hours.

**AMERICAN BOARD OF INTERNAL MEDICINE MOC II CREDIT:** Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**AMERICAN BOARD OF PEDIATRICS MOC PART II CREDIT:** Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 MOC points in the American Board of Pediatrics's (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

**OTHER HEALTHCARE PROFESSIONAL CREDIT:** Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME, please consult your professional licensing board.



AT THE FOREFRONT

# UChicago Medicine

The University of Chicago  
Center for Continuing  
Medical Education  
5841 S. Maryland Ave., MC 1137  
Chicago, IL 60637

Follow us on Twitter: @UChicagoCME




**FOR MORE INFORMATION AND TO REGISTER:**

Scan the QR code or visit [www.ChicagoPostASH.com](http://www.ChicagoPostASH.com)

**QUESTIONS?** Contact Meeting Achievements at

[kristen@meetingachievements.com](mailto:kristen@meetingachievements.com) -or- 219.465.1115



THE UNIVERSITY OF CHICAGO

# ANNUAL UPDATES FROM ASH 2023

## PRACTICE CHANGING ABSTRACTS

# FRIDAY MARCH 1, 2024

## HYBRID FORMAT: VIRTUAL + LIMITED IN-PERSON ATTENDANCE

### COURSE DIRECTOR

Michael Bishop, MD | Professor of Medicine  
Director of the Jonas Center for Cellular Therapy  
University of Chicago Medicine

# [www.ChicagoPostASH.com](http://www.ChicagoPostASH.com)

CONTINUING EDUCATION ACCREDITATION BY UNIVERSITY OF CHICAGO



AT THE FOREFRONT

# UChicago Medicine

## PROGRAM INFORMATION

### COURSE DESCRIPTION

This activity's goal is to join community-based providers and academic oncologists to improve the care and outcomes of patients with hematologic malignancies. To reach this goal, this activity will address early treatment options and medical advances that can be implemented to reduce cancer-related deaths, including CAR T-cell therapy, other novel immunotherapies, and targeted agents for the state-of-the-art management of newly diagnosed and relapsed blood cancers. It will keep all healthcare professionals who care for patients with hematologic malignancies abreast of the latest scientific updates, innovative ideas, and timeliest issues related to patients they care for with these diseases.

It will also provide participants with information to improve patient management and care strategies. They will discuss rapidly evolving developments among new and available treatments, discuss and debate important considerations in treatment sequencing among novel agents and improve practice paradigms for patients across all treatment settings. This activity will educate them on best practices for treating hematologic cancers and inform them of the indications to refer a patient for expert quaternary level care at centers such as the University of Chicago, including clinical trial options for patients.

### TARGET AUDIENCE

This activity is designed for hematologists, medical oncologists, pathologists, fellow and resident trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to the treatment of hematologic cancers.

### LEARNING OBJECTIVES

After this activity, participants will be able to:

1. Illustrate how cutting-edge data presented at the 2023 Annual Meeting of the American Society of Hematology can apply to clinical practice;
2. Discuss the emerging treatment strategies, the role of targeted agents in therapeutic paradigms for patients with myeloid malignancies, and available clinical trial options and other approaches to patients with relapsed/refractory disease;
3. Discuss the optimal patient selection, timing, and regimens for stem cell transplantation with high-risk and relapsed/refractory disease;
4. Interpret emerging clinical trial data in the context of CAR T-cell therapy for lymphoid malignancies and its place in evolving hematologic malignancy treatment standards;
5. Evaluate the available treatments for the care of patients with lymphoma based on optimal treatment sequencing, novel agents and their role in earlier lines of therapy, and how these change best practices for evidence-based care of both newly diagnosed and relapsed/refractory cases;
6. Discuss evolving treatment paradigms and therapy sequencing for novel agents in the care of patients with multiple myeloma, including approved and emerging CAR T-cell therapies, as well as bispecific antibodies with varied therapeutic targets;
7. Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common benign hematologic diseases including newly approved therapeutic classes;
8. Discuss international trends in the care of hematologic malignancies.

### CONFERENCE LOCATION

#### IN-PERSON:

Convene | 333 N Green Street | Chicago, IL 60607

#### VIRTUAL:

Log in information will be sent 72 hours prior to conference.

## AGENDA: MARCH 1, 2024

### PRE-CONFERENCE

8:00 am **REGISTRATION/  
BREAKFAST /  
MEET & GREET** (in-person)

8:30 am **Fellows Meet the Expert**  
Speaker  
Noopur Raje, MD

9:00 am **Updates in Hematologic  
Pharmacology**  
Moderator  
Speakers  
Jennifer Collins, PharmD, BCOP  
Emily Dworkin, PharmD, BCOP  
Kaitlin Kelly, PharmD, BCOP

9:30 am **CONCURRENT SESSIONS**  
**Fellows: Case Based  
Clinical Trial Considerations**  
Moderators  
Speakers  
Alexandra Rojek, MD  
Rafael Madero-Marroquin, MD  
Joseph Cannova, MD  
Samuel Yates, MD

**APP + Nursing Session**  
Moderator  
Speaker  
Mylove Mortel, MSPH, RN, OCN  
TBD

10:30 am **BREAK | VISIT EXHIBITS |  
NETWORKING**

### MAIN CONFERENCE

11:00 am **KEYNOTE: Myeloma**  
Moderator  
Speaker  
Andrzej Jakubowiak, MD, PhD  
Noopur Raje, MD

12:00 pm **LUNCH | VISIT EXHIBITS |  
NETWORKING**

1:00 pm **HL & NHL**  
Speaker  
Sonali Smith, MD

1:30 pm **BREAK | VISIT EXHIBITS |  
NETWORKING**

1:45 pm **Updates in Myelofibrosis,  
MPN, MDS**  
Moderator  
Speaker  
Olatoyosi Odenike, MD  
Satya Kosuri, MD

2:15 pm **Updates in AML**  
Moderator  
Speaker  
Olatoyosi Odenike, MD  
Anand Patel, MD

2:45 pm **BREAK | VISIT EXHIBITS |  
NETWORKING**

3:00 pm **Panel: CLL (CAR, Co-op  
Trials, BTKI tox, ...)**  
Moderator  
Speakers  
Sonali Smith, MD  
Michael Thirman, MD  
Peter Riedell, MD  
Justin Kline, MD

3:30 pm **Updates in Myeloma**  
Speaker  
Benjamin Derman, MD

4:00 pm **Updates in Transplantation**  
Speaker  
Adam Duvall, MD

4:25 pm **Updates in Cellular  
Therapy/Non-cell Therapy  
for Acute Leukemias  
(AML/ALL)**  
Speaker  
Miriam Nawas, MD

4:50 pm **Closing Remarks**  
Michael Bishop, MD

5:00 pm **ADJOURN/RECEPTION**

*Michael Bishop, MD will be the Moderator unless indicated otherwise.*

## FACULTY

### COURSE DIRECTOR



**Michael Bishop, MD**  
Professor of Medicine  
Director of the Jonas Center  
for Cellular Therapy  
University of Chicago Medicine

### KEYNOTE SPEAKER



**Noopur Raje, MD**  
Massachusetts  
General Hospital,  
Harvard Medical School  
Director,  
Center for Multiple Myeloma  
Professor of Medicine

### UNIVERSITY OF CHICAGO FACULTY

**Joseph Cannova, MD**  
Fellow

**Jennifer Collins,  
PharmD, BCOP**  
Clinical Pharmacy Specialist -  
Hematology/Oncology

**Benjamin Derman, MD**  
Assistant Professor of Medicine

**Adam Duvall, MD, MPH**  
Assistant Professor of Medicine

**Emily Dworkin,  
PharmD, BCOP**  
Clinical Pharmacy Specialist

**Andrzej Jakubowiak,  
MD, PhD**  
Professor of Medicine  
Director, Myeloma Program

**Kaitlin Kelly,  
PharmD, BCOP**  
Clinical Pharmacy Specialist

**Justin Kline, MD**  
Associate Professor of Medicine  
Director, Lymphoma Program

**Satyajit Kosuri, MD**  
Assistant Professor of Medicine

**Rafael Madero-  
Marroquin, MD**  
Fellow

**Mylove Mortel, MSPH,  
RN, OCN**  
Assistant Director of Clinical  
Operations

**Mariam Nawas, MD**  
Assistant Professor of Medicine

**Toyosi Odenike, MD**  
Professor of Medicine  
Director, Leukemia Program

**Anand Patel, MD**  
Assistant Professor of Medicine

**Peter Riedell, MD**  
Assistant Professor of Medicine

**Alexandra Rojek, MD**  
Fellow

**Sonali Smith, MD**  
Elwood V. Jensen  
Professor in Medicine  
Chief, Section of  
Hematology & Oncology

**Michael Thirman, MD**  
Associate Professor of Medicine

**Samuel Yates, MD**  
Fellow



**FOR MORE  
INFORMATION AND  
TO REGISTER SCAN  
THE QR CODE OR VISIT:**

**REGISTER TODAY:** [www.ChicagoPostASH.com](http://www.ChicagoPostASH.com)